gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Solute carrier family 45, member 3

SLC45A3, Prostein, PRST
Top mentioned proteins: TMPRSS2, CAN, ER81, SAP1, PEA3
Papers on SLC45A3
Fine mapping and resequencing of the PARK16 locus in Parkinson's disease.
Toft et al., Oslo, Norway. In J Hum Genet, Jul 2015
Targeted resequencing of the full coding regions of SLC45A3, NUCKS1, RAB7L1, SLC41A1 and PM20D1 was performed in DNA pools from a subset of 387 patient samples.
Prostate cancer marker panel with single cell sensitivity in urine.
Petrovics et al., Bethesda, United States. In Prostate, Jul 2015
Cells captured on the membrane were assayed for PSA and Prostein expression to identify prostate epithelial cells, and for ERG and AMACR to identify prostate tumor cells.
Genetic variants at 1q32.1, 10q11.2 and 19q13.41 are associated with prostate-specific antigen for prostate cancer screening in two Korean population-based cohort studies.
Jee et al., Seoul, South Korea. In Gene, Mar 2015
The top SNP associated with log PSA levels was rs2153904 in SLC45A3 (p values, 5.24×10(-9) to 2.00×10(-6)).
Proton-associated sucrose transport of mammalian solute carrier family 45: an analysis in Saccharomyces cerevisiae.
Vitavska et al., Osnabrück, Germany. In Biochem J, 2015
The members of the solute carrier 45 (SLC45) family have been implicated in the regulation of glucose homoeostasis in the brain (SLC45A1), with skin and hair pigmentation (SLC45A2), and with prostate cancer and myelination (SLC45A3).
Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?
Lu et al., Hangzhou, China. In Omics, 2014
In 105 prostate cancer samples and case-matched adjacent nonmalignant tissues, we determined the expression level of USP9Y-TTTY15 and a previously reported transcription-induced chimeric RNA, SLC45A3-ELK4.
A genome-wide association study of serum levels of prostate-specific antigen in the Japanese population.
Matsuda et al., Kyoto, Japan. In J Med Genet, 2014
RESULTS: Rs16856139 in SLC45A3, the same region as the previous Chinese study, showed an overall significant association with PSA levels (p=2.4×10(-11))
A comparative study of ERG status assessment on DNA, mRNA, and protein levels using unique samples from a Swedish biopsy cohort.
Rubin et al., Trento, Italy. In Appl Immunohistochem Mol Morphol, 2013
This genetic aberration, most commonly leading to the TMPRSS2-ERG fusion, but also SLC45A3-ERG or NDRG1-ERG fusions, all leading to an overexpression of a truncated ERG protein.
Novel 5' fusion partners of ETV1 and ETV4 in prostate cancer.
Teixeira et al., Porto, Portugal. In Neoplasia, 2013
We additionally describe two novel gene fusion combinations of previously described genes, namely, SLC45A3-ETV4 and HERVK17-ETV4.
Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system.
Perner et al., Bonn, Germany. In Histol Histopathol, 2013
For IHC experiments, one nucleus specific marker (i.e., ERG antibody), one cytoplasmic specific marker (i.e., SLC45A3 antibody), and one marker expressed in both compartments (i.e., TMPRSS2 antibody) were chosen.
Genome-wide association study identified novel genetic variant on SLC45A3 gene associated with serum levels prostate-specific antigen (PSA) in a Chinese population.
Mo et al., Winston-Salem, United States. In Hum Genet, 2013
The three regions are located on 1q32.1 at SLC45A3, 10q11.23 at MSMB, and 19q13.33 at KLK3.
Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Kristiansen et al., Bonn, Germany. In Int J Cancer, 2013
The second most common 5' fusion partner after TMPRSS2 is SLC45A3.
SLC45A3-ELK4 chimera in prostate cancer: spotlight on cis-splicing.
Chinnaiyan et al., Ann Arbor, United States. In Cancer Discov, 2012
Using a series of detailed experiments, Zhang and colleagues establish that the prostate cancer RNA chimera SLC45A3-ELK4 is generated by cis-splicing between the 2 adjacent genes and does not involve DNA rearrangements or trans-splicing.
Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database.
Sasaki et al., Sendai, Japan. In Surg Today, 2012
The results revealed the panels of immunohistochemical markers for the differential diagnosis of rectal adenocarcinoma, in which [+] designates positivity in rectal adenocarcinoma and [-] designates negativity in rectal adenocarcinoma: from bladder adenocarcinoma, CDX2[+], VIL1[+], KRT7[-], THBD[-] and UPK3A[-]; from prostate adenocarcinoma, CDX2[+], VIL1[+], CEACAM5[+], KLK3(PSA)[-], ACPP(PAP)[-] and SLC45A3(prostein)[-]; and from ovarian mucinous adenocarcinoma, CEACAM5[+], VIL1[+], CDX2[+], KRT7[-] and MUC5AC[-].
Diagnostic utility of p63/P501S double sequential immunohistochemical staining in differentiating urothelial carcinoma from prostate carcinoma.
Parwani et al., Pittsburgh, United States. In Diagn Pathol, 2010
Double sequential immunohistochemical staining with p63 and P501S is highly specific and can be a useful tool in distinguishing urothelial carcinoma from prostate carcinoma.
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma.
Chinnaiyan et al., Ann Arbor, United States. In Nat Med, 2010
Here we used paired-end transcriptome sequencing to screen ETS rearrangement-negative prostate cancers for targetable gene fusions and identified the SLC45A3-BRAF (solute carrier family 45, member 3-v-raf murine sarcoma viral oncogene homolog B1) and ESRP1-RAF1 (epithelial splicing regulatory protein-1-v-raf-1 murine leukemia viral oncogene homolog-1) gene fusions.
Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort.
Rubin et al., New York City, United States. In Mod Pathol, 2010
This is the first study to report concurrent TMPRSS2 and SLC45A3 rearrangements in the same tumor focus in prostate cancer
N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer.
Rubin et al., New York City, United States. In Neoplasia, 2009
This study demonstrates that most ERG-overexpressing prostate cancers harbor hormonally regulated TMPRSS2-ERG, SLC45A3-ERG, or NDRG1-ERG fusions
Transcriptome sequencing to detect gene fusions in cancer.
Chinnaiyan et al., Ann Arbor, United States. In Nature, 2009
SLC45A3-ELK4 may represent the first description of a recurrent RNA chimaeric transcript specific to prostate cancer that does not have a detectable DNA aberration
Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells.
Barik et al., Mobile, United States. In J Mol Med (berl), 2008
Intronic miRNAs from tissue-specific transcripts, or their natural absence, make cardinal contributions to cellular gene expression and phenotype.
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
Chinnaiyan et al., Ann Arbor, United States. In Nature, 2007
We identified previously unknown 5' fusion partners in prostate tumours with ETV1 outlier expression, including untranslated regions from a prostate-specific androgen-induced gene (SLC45A3) and an endogenous retroviral element (HERV-K_22q11.23), a prostate-specific androgen-repressed gene (C15orf21), and a strongly expressed housekeeping gene (HNRPA2B1).
share on facebooktweetadd +1mail to friends